Microtubule inhibitor (specialist)
Eribulin
Brand names: Halaven
Adult dose
Dose: 1.23mg/m² IV bolus on days 1 and 8 of 21-day cycle
Route: IV
Frequency: Days 1 & 8 q21d
Clinical pearls
- NICE TA423 / TA515: locally advanced or metastatic breast cancer (≥2 prior chemotherapy regimens including anthracycline + taxane); also liposarcoma
- ESMO breast cancer / sarcoma guidelines
- Specialist oncology
Contraindications
- Hypersensitivity
- Severe hepatic impairment (dose-adjust)
- Pregnancy
Side effects
- Neutropaenia (often dose-limiting)
- Peripheral neuropathy
- Fatigue
- Alopecia
- QT prolongation
- Anaemia
- Mucositis
Interactions
- QT-prolonging drugs
Monitoring
- FBC
- LFTs
- Neuropathy
- ECG
- Electrolytes (K, Mg)
Reference: BNF; NICE TA423; NICE TA515; ESMO; SmPC; https://bnf.nice.org.uk/drugs/eribulin-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia